Veracyte VCYT Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 70.1%+3.2pp | 66.9%+3.3pp | 63.6%+4.4pp | 59.2%— | |
| Operating margin | 11.2%+7.6pp | 3.6%+27.4pp | -23.8%-9.9pp | -13.9%+23.5pp | |
| Net margin | 12.8%+7.4pp | 5.4%+26.0pp | -20.6%-8.3pp | -12.3%+22.1pp | |
| Returns | |||||
| Return on equity | 5.3%+3.2pp | 2.2%+9.2pp | -7%-3.7pp | -3.4%+6.6pp | |
| Return on invested capital | 5.9%+4.1pp | 1.8%+11.4pp | -9.7%-5.3pp | -4.4%+11.6pp | |
| Efficiency | |||||
| Asset turnover | 0.4×0.0× | 0.4×+0.1× | 0.3×+0.1× | 0.3×0.0× | |
| Liquidity | |||||
| Current ratio | 8.1×+3.4× | 4.7×+0.1× | 4.7×+0.7× | 4×+0.2× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -4.1×+0.7× | -4.8×— | —— | —— | |
| Per Share | |||||
| Book value per share | $16.25+8.0% | $15.05+4.7% | $14.37-4.4% | $15.03-7.0% | |
| Valuation | |||||
| Market capitalization | $3.33B+8.4% | $3.07B+52.6% | $2.01B+18.1% | $1.7B-41.8% | |
| Price / earnings | 50.2×-77.0× | 127.1×— | —— | —— | |
| Price / sales | 6.4×-0.4× | 6.9×+1.3× | 5.6×-0.2× | 5.7×-7.6× | |
| Price / book | 2.5×-0.1× | 2.6×+0.7× | 1.9×+0.3× | 1.6×-1.1× | |
| EV / EBITDA | 37.9×-34.8× | 72.7×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Veracyte's profit margins?
- Veracyte (VCYT) runs a 70.9% gross margin and a 14.3% operating margin, with a 16.2% net margin.
- Where do Veracyte's ratios come from?
- Every ratio is computed from Veracyte's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
